22nd August 2019
Approach to artificial pancreas called ‘very ambitious but well-conceived’
CLOSE, an EIT Health Innovation Project, takes a much-needed and productive approach to achieving greater use of an artificial pancreas (AP) for type-2 diabetes (T2D), according to an article in “Journal of Diabetes Science and Technology”, published 19 January 2019.
“This is a very ambitious but well-conceived and delineated project which takes into consideration most of the relevant factors that may influence AP implementation in T2D care,” according to the article by Andrew A. Bremer, of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Guillermo Arreaza-Rubin, of the National Institute of Diabetes and Digestive and Kidney Diseases.
The authors said that they expect the outcome of the CLOSE project will be to inform the creation of future treatment guidelines. They recommend that the CLOSE approach be applied to other emerging diabetes technologies by testing them with a model like “AP Plus”, the multi-stakeholder solution advocated by the CLOSE project.
Bremer and Arreaza-Rubin’s article was based on a review of a 21 September 2018 article in the same journal by Freimut Schliess, leader of the CLOSE project, and a consortium of 20 additional co-authors, including Jan-Philipp Beck, CEO of EIT Health. That article, entitled “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project”, detailed the workings of the CLOSE project.
AI tool for COVID-19 produces significant results
EIT Health project aids personalised medicine
EIT Health helps Tubulis secure €10.7M in funding
Investor Network aids firm doing antibody work
EIT Health-backed start-ups garner big investments
A million each for iLoF and Restorative Neurotechnologies